J. Marc Pipas
GeoVax (United States) · 108 works · 3,333 citations · h-index 25
Top works
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
- Analysis of MicroRNAs in Pancreatic Fine-Needle Aspirates Can Classify Benign and Malignant Tissues
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors.
- Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas
- Brain Metastases from Colorectal Cancer: Risk Factors, Incidence, and the Possible Role of Chemokines
- Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma
- Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581
- MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma
- Molecular Profiling of Appendiceal Epithelial Tumors Using Massively Parallel Sequencing to Identify Somatic Mutations
- Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature
- Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study
- Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinoma
- Effect of Initiating a Multidisciplinary Care Clinic on Access and Time to Treatment in Patients With Pancreatic Adenocarcinoma
- Endovascular Recanalization of Symptomatic Portomesenteric Venous Obstruction after Pancreaticoduodenectomy and Radiation
- MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm
- A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
- Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma
- A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma
- The ENABLE III randomized controlled trial of concurrent palliative oncology care.